abrdn plc Grows Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

abrdn plc boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 713.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 511,986 shares of the company’s stock after buying an additional 449,053 shares during the quarter. abrdn plc’s holdings in Teva Pharmaceutical Industries were worth $5,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Blue Trust Inc. increased its position in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after buying an additional 2,180 shares during the last quarter. Signaturefd LLC increased its position in Teva Pharmaceutical Industries by 90.8% in the third quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after buying an additional 2,394 shares during the last quarter. Desjardins Global Asset Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 15.2% in the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after purchasing an additional 1,070 shares in the last quarter. Schechter Investment Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $117,000. Finally, DGS Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at $119,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TEVA has been the subject of several recent research reports. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $12.00 to $19.00 in a research report on Monday, February 12th. Barclays lifted their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Finally, Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price objective for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $13.81 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. The business has a 50-day moving average price of $13.51 and a two-hundred day moving average price of $11.40. Teva Pharmaceutical Industries Limited has a 12-month low of $7.09 and a 12-month high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $13.15, for a total value of $980,069.50. Following the transaction, the chief executive officer now owns 87,125 shares in the company, valued at $1,145,693.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock valued at $5,132,766 over the last 90 days. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.